ArticlePloS one2011
Identification of lactoferricin B intracellular targets using an Escherichia coli proteome chip.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Bacterial Acyl Carrier Proteins Are a Cytoplasmic Target for Different Cationic Antimicrobial and Antibiofilm Peptides.International journal of molecular sciences · 2026Article
- Testing Antimicrobial Properties of Human Lactoferrin-Derived Fragments.International journal of molecular sciences · 2023Article
- Design and Evaluation of Short Bovine Lactoferrin-Derived Antimicrobial Peptides against Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- The Role of Antimicrobial Peptides as Antimicrobial and Antibiofilm Agents in Tackling the Silent Pandemic of Antimicrobial Resistance.Molecules (Basel, Switzerland) · 2022Review
- Multiple roles of ribosomal antimicrobial peptides in tackling global antimicrobial resistance.Royal Society open science · 2022Article
- Fungicidal Activity of Recombinant Javanicin againstMolecules (Basel, Switzerland) · 2021Article
- Systematical Screening of Intracellular Protein Targets of Polyphemusin-I UsingInternational journal of molecular sciences · 2021Article
- Systematic Identification of Protein Targets of Sub5 UsingInternational journal of molecular sciences · 2021Article
- Article
- Antimicrobial Susceptibility Testing of Antimicrobial Peptides to Better Predict Efficacy.Frontiers in cellular and infection microbiology · 2020Review
- Systematical Analysis of the Protein Targets of Lactoferricin B and Histatin-5 Using Yeast Proteome Microarrays.International journal of molecular sciences · 2019Article
- Antimicrobial peptides: biochemical determinants of activity and biophysical techniques of elucidating their functionality.World journal of microbiology & biotechnology · 2018Review
- Antimicrobial Activity of Truncated and Polyvalent Peptides Derived from the FKCRRQWQWRMKKGLA Sequence against Escherichia coli ATCC 25922 and Staphylococcus aureus ATCC 25923.Molecules (Basel, Switzerland) · 2017Article
- Intracellular Targeting Mechanisms by Antimicrobial Peptides.Antimicrobial agents and chemotherapy · 2017Review
- Synthetic Peptides Derived from Bovine Lactoferricin Exhibit Antimicrobial Activity against E. coli ATCC 11775, S. maltophilia ATCC 13636 and S. enteritidis ATCC 13076.Molecules (Basel, Switzerland) · 2017Article
- Revealing the sequence of interactions of PuroA peptide with Candida albicans cells by live-cell imaging.Scientific reports · 2017Article
- The Anticancer Peptide TAT-RasGAPFrontiers in microbiology · 2017Article
- Antimicrobial Activity of Lactoferrin-Related Peptides and Applications in Human and Veterinary Medicine.Molecules (Basel, Switzerland) · 2016Review
- Systematic Analysis of Intracellular-targeting Antimicrobial Peptides, Bactenecin 7, Hybrid of Pleurocidin and Dermaseptin, Proline-Arginine-rich Peptide, and Lactoferricin B, by Using Escherichia coli Proteome Microarrays.Molecular & cellular proteomics : MCP · 2016Article
- Suppression of the toxicity of Bac7 (1-35), a bovine peptide antibiotic, and its production in E. coli.AMB Express · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lactoferricin B (LfcinB) is a well-known antimicrobial peptide. Several studies have indicated that it can inhibit bacteria by affecting intracellular activities, but the intracellular targets of this antimicrobial peptide have not been identified. Therefore, we used E. coli proteome chips to identify the intracellular target proteins of LfcinB in a high-throughput manner. We probed LfcinB with E. coli proteome chips and further conducted normalization and Gene Ontology (GO) analyses. The results of the GO analyses showed that the identified proteins were associated with metabolic processes. Moreover, we validated the interactions between LfcinB and chip assay-identified proteins with fluorescence polarization (FP) assays. Sixteen proteins were identified, and an E. coli interaction database (EcID) analysis revealed that the majority of the proteins that interact with these 16 proteins affected the tricarboxylic acid (TCA) cycle. Knockout assays were conducted to further validate the FP assay results. These results showed that phosphoenolpyruvate carboxylase was a target of LfcinB, indicating that one of its mechanisms of action may be associated with pyruvate metabolism. Thus, we used pyruvate assays to conduct an in vivo validation of the relationship between LfcinB and pyruvate level in E. coli. These results showed that E. coli exposed to LfcinB had abnormal pyruvate amounts, indicating that LfcinB caused an accumulation of pyruvate. In conclusion, this study successfully revealed the intracellular targets of LfcinB using an E. coli proteome chip approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.